Rubicon Research to Acquire 85% Stake in Arinna Lifesciences for Pharmaceutical Growth
Rubicon Research Limited has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences Limited. Following this acquisition, Arinna Lifesciences will become a subsidiary of Rubicon Research Limited.Arinna Lifesciences Limited is a branded pharmaceutical marketing company based in Ahmedabad, India. The company specializes in the marketing of branded pharmaceutical products within the Indian domestic market, focusing particularly on the CNS (Central Nervous System) and neuro-psychiatric therapeutic segment. Arinna's product portfolio includes items such as antiepileptics, antidepressants/thymoleptics, and antipsychotics. The company maintains a commercial model that utilizes a dedicated field force to engage with prescribers across India.
The strategic acquisition aims to further Rubicon’s strategy of leveraging its intellectual property (IP) and chronic products portfolio to unlock growth in key markets. The deal is expected to provide Rubicon with access to Arinna's established sales and distribution network, enhancing its reach to patients and prescribers for differentiated offerings and its strong pipeline of specialty products and drug-device combinations.
Transaction and Financial Details
The acquisition is structured using cash consideration. The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt free basis. After accounting for necessary adjustments, the purchase consideration for the 85% equity shareholding in Arinna has been determined to be approximately INR 175.92 Crores. This acquisition is based on a fully diluted price of approximately INR 158.53 per share.The expected completion timeline for the acquisition is within one month from the date of signing the transaction documents, or by such other timelines mutually agreed upon by the parties.
The transaction details, including the company's background and financials, are summarized below:
| Particulars | Detail |
|---|---|
| Target Entity Name | Arinna Lifesciences Limited |
| Industry | Pharmaceuticals |
| Acquisition Stake | 85% |
| Consideration Type | Cash |
| Valuation (Enterprise Value) | INR 200 Crores (Cash and Debt Free Basis) |
| Purchase Consideration | Approximately INR 175.92 Crores |
| Price per Share | Approximately INR 158.53 |
Arinna Lifesciences Turnover History
The background of Arinna Lifesciences Limited shows a steady growth trajectory over the past three fiscal years, with its turnover details presented in the table below:| Fiscal Year | Turnover |
|---|---|
| FY 2024-25 | INR 71.50 crores |
| FY 2023-24 | INR 65.14 crores |
| FY 2022-23 | INR 60.06 crores |
The company was incorporated on August 29, 2013, and operates in India. Furthermore, the acquisition does not fall within related party transactions, and neither Rubicon Research Limited nor its promoter group has any existing interest in Arinna Lifesciences Limited.
Stock Price Movement
Rubicon Research Ltd shares finished Wednesday at ₹819.95, edging higher by 0.04% at the close of trading. The stock traded within a fairly tight range today, hitting a low of ₹819.95 and a high of ₹838.95.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.